Oncopeptides has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO, Jakob Lindberg, has been terminated. In their

Oncopeptides has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO, Jakob Lindberg, has been terminated. In their
The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid
The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to the company’s lead asset mitazalimab for the treatment of pancreatic cancer. “This designation is a key milestone
On behalf of the Swedish government, the Swedish innovation agency Vinnova has decided on funding of an innovation cluster for commercialization, competence development and production capacity for advanced therapies. The
The money has been raised for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for an ongoing proof-of-concept study
BioLamina announces the release of the first Biolaminin 521 LN batches issued from its new manufacturing facility in Sundbyberg, Sweden. The products, which are now ready for commercialization, have been
Swedish Orphan Biovitrum (Sobi) has entered into an agreement and plan of merger with CTI BioPharma (CTI) under which Sobi has agreed to acquire CTI, by means of a tender
Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. “Koselugo
The company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines
Ranibizumab biosimilar is being launched in major European markets. Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane Biopharma, marking Xbrane’s first commercial
The Roddenberry Foundation has announced the six awardees of its biennial 1.5 million USD Prize to support audacious early-stage science and technology ventures that contribute to the United Nations Development
Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2
The company has been awarded a grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute. The grant will fund